Shots:
- The Chinese NMPA has approved PanTRKare NTRK1/2/3 Gene Fusion Detection Kit as a companion diagnostic for Roche’s Rozlytrek (entrectinib)
- The kit was validated through a large-scale study across 33 tumor types & 2,400+ clinical samples, where it demonstrated high accuracy, sensitivity, & reproducibility, with detection of 200+ unique NTRK fusion variants
- Also, clinical bridging studies with Rozlytrek demonstrated high concordance between test results & comparable ORR in pts with NTRK fusion–positive tumors
Ref: PRNewswire | Image: Geneseeq| Press Release
Related News:- Johnson & Johnson MedTech Launches Shockwave Javelin Peripheral IVL Catheter in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
